J.P. Morgan·2026-11-03CompanyNeutral$30Pfizer Inc. (PFE.US) 3Q Takeaways – Decent Qtr, Pipeline Progression Key to Story From Here
Goldman Sachs·2026-10-26CompanyNeutral$26Pfizer Inc. (PFE.US): 25-Valent PCV Phase 2 Infant Data Look Strong
J.P. Morgan·2026-10-09CompanyNeutral$28 → $30▲Pfizer Inc. (PFE.US) 3Q Earnings Preview – Anticipating Another Eliquis Driven Guidance Raise
Goldman Sachs·2026-08-05CompanyNeutral$26Pfizer Inc. (PFE.US): Continued Steady Operational Execution; Pipeline Execution More Important
Bernstein·2026-10-25SectorMarket-PerformUS Biopharmaceuticals: US Biopharma @ ESMO-the most impactful data presented thus far (& implications for our coverage)
Goldman Sachs·2026-10-23SectorGLOBAL HEALTHCARE: PHARMACEUTICALS: Analysing Oncology Specialist Prescribing trends into ESMO
Goldman Sachs·2026-08-24Company3SBio Inc. (1530.HK): Earnings Review: Mixed 1H with Weak Product Sales and Resilient Earnings; Innovation Momentum Continues